The change is due to regulatory caution over whether the AstraZeneca vaccine is safe and effective for older adults. While the vaccine has been approved by EU and Italian regulators for use on all adults, clinical trials to date have mainly involved participants under 55, leading Italian medicines agency AIFA to recommend that it be reserved for 18 to 55-year-olds pending further studies.
When the first million doses arrive this month, they will therefore be offered to teachers, lecturers and other staff in schools and universities, as well as members of the armed forces, police, firefighters, prison staff and prisoners, other key workers and people living in religious or other shared communities who are under 55.
Those over 55 or with health conditions including arterial hypertension, cancer, diabetes, cardiovascular disease, severe obesity and others will receive either the Pfizer-BioNTech or Moderna shot, around 2.5 million doses of which are due to arrive throughout February.